Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse
Status:
Completed
Trial end date:
2019-05-13
Target enrollment:
Participant gender:
Summary
To test the preliminary efficacy of 16.0 mg of Prazosin daily versus placebo in treatment
seeking alcohol dependent individuals. This proposal is a laboratory and treatment outcome
study to examine the effects of Prazosin on brief exposure to stress, drug cues and neutral
situations on alcohol and drug craving, mood and neurobiological reactivity in a sample of
cocaine and/or alcohol dependent individuals. Prazosin will be beneficial for reduction in
stress and alcohol cue induced craving and related arousal. In a sample of treatment-seeking
alcohol dependent men and women, we propose to examine (a) differences in measures of alcohol
craving, emotion state, hypothalamic-pituitary-adrenal (HPA) activation, physiological
arousal and plasma catecholamine response to stress imagery and to alcohol cue imagery as
compared to neutral imagery; (b) reduction in alcohol abstinence symptoms; and (c)
improvement in alcohol treatment outcomes as measured by reductions in heavy drinking days,
any drinking days, secondarily on drinks/day, anxiety, mood and sleep.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Yale University
Collaborators:
National Institute on Alcohol Abuse and Alcoholism (NIAAA) National Institutes of Health (NIH)